for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arca Biopharma Inc

ABIO.OQ

Latest Trade

5.35USD

Change

0.02(+0.38%)

Volume

22,871

Today's Range

5.27

 - 

5.50

52 Week Range

4.72

 - 

20.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.33
Open
5.27
Volume
22,871
3M AVG Volume
0.85
Today's High
5.50
Today's Low
5.27
52 Week High
20.40
52 Week Low
4.72
Shares Out (MIL)
1.59
Market Cap (MIL)
8.53
Forward P/E
-1.22
Dividend (Yield %)
--

Next Event

Q4 2019 ARCA Biopharma Inc Earnings Release

Latest Developments

More

ARCA Biopharma Reports Q3 Loss Per Share Of $0.76

Arca Biopharma Posts Q2 Loss Per Share Of $1.14

Arca Biopharma Says Cash As Of March 31 To Be Sufficient To Fund Operations Through Q1 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arca Biopharma Inc

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry

Biotechnology & Drugs

Contact Info

11080 Circle Point Rd Ste 140

+1.720.9402200

http://arcabio.com/

Executive Leadership

Robert E. Conway

Chairman of the Board

Michael R. Bristow

President, Chief Executive Officer, Director

Thomas A. Keuer

Chief Operating Officer

Christopher David Ozeroff

Senior Vice President, General Counsel, Secretary

Brian L. Selby

Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.098

2018

-10.262

2019(E)

-4.420
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-70.64
Return on Equity (TTM)
-62.47

Latest News

Latest News

BRIEF-Arca Biopharma Q1 Loss Per Share $0.20

* ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Arca Biopharma And Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

* ARCA BIOPHARMA AND MEDTRONIC EXTEND GENCARO CLINICAL TRIAL COLLABORATION AGREEMENT

BRIEF-ARCA Biopharma Anticipates Meeting With FDA In Q2

* ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL

BRIEF-Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods

* Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting

BRIEF-ARCA Biopharma announces third quarter financial results

* ARCA Biopharma announces third quarter 2017 financial results and provides business update

BRIEF-ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trial​

* ARCA Biopharma announces GENETIC-AF data and safety monitoring board recommendation to complete Phase 2B GENETIC-AF clinical trial based on efficacy and safety data in phase 2b interim analysis

BRIEF-Arca Biopharma Q2 loss per share $0.59

* Arca Biopharma announces second quarter 2017 financial results and provides business update

BRIEF-ARCA Biopharma announces database lock for genetic-af phase 2b interim efficacy analysis

* ARCA Biopharma announces database lock for genetic-af phase 2b interim efficacy analysis – dsmb recommendation anticipated in august 2017 Source text for Eikon: Further company coverage:

BRIEF-ARCA Biopharma Q1 loss per share $0.48

* Arca biopharma announces first quarter 2017 financial results and provides business update

BRIEF-Arca Biopharma announces 200th patient randomized into the genetic-AF phase 2b/3 clinical trial

* Arca Biopharma announces 200th patient randomized into the genetic-AF seamless design phase 2b/3 clinical trial

BRIEF-Arca Biopharma Inc files for mixed shelf of up to $75 mln

* Arca Biopharma Inc files for mixed shelf of up to $75 million Source text :(http://bit.ly/2piU0GX) Further company coverage:

BRIEF-ARCA Biopharma 2016 net loss $16.4 mln, or $1.81 per share

* Arca biopharma announces fiscal year 2016 financial results and provides business update

BRIEF-Arca Biopharma entered into capital on demand sales agreement with Jonestrading Institutional Services LLC on Jan 11

* On Jan 11 co entered into capital on demand(tm)sales agreement with jonestrading institutional services llc - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up